GoldenGolden
Advanced Search
Agios Pharmaceuticals

Agios Pharmaceuticals

Agios Pharmaceuticals is a public American pharmaceutical company

Agios Pharmaceuticals is a company that develops and discovers biopharmaceutical therapeutics for the research of cancer metabolism. The company was founded by Craig Thompson, Lewis Cantley, and Tak Mak, in 2008, in Cambridge, Massachusetts, United States.

The company develops drugs that also focus on glycolysis, fatty acid metabolism, and autophagy, as well as hematologic malignancies, solid tumors, and rare genetic diseases. Agios' drugs are focused on cellular metabolism and precision medicine. Some of their products include Mitapivat and Vorasidenib, and other intensive chemotherapies.

Agios' two approved oncology precision medicines are meant to provide new insights and potential therapeutic approaches, and tthe company is growing their preclinical, clinical and commercial programs.

COVID-19

Agios Pharmaceuticals is continued to provide their commercial medicine TIBSOVO during the COVID-19 pandemic to their patients in the United States. International and domestic business was stopped during the pandemic as the company required their employees to work from home.

Timeline

May 31, 2017
Agios Pharmaceuticals was founded by Craig Thompson and Lewis C. Cantley.
November 17, 2011
Agios Pharmaceuticals raises a $78,000,000 series C round from ARCH Venture Partners, Celgene, Flagship Pioneering and Third Rock Ventures.
July 2008
Agios Pharmaceuticals raises a $33,000,000 series A round from ARCH Venture Partners, Flagship Pioneering and Third Rock Ventures.

Funding rounds

People

Name
Role
LinkedIn

Abhishek Jha

Employee

Amit Patel

Investor

Christopher Dovletoglou

Employee

Darrin Miles

Employee

Fay Xing

Investor

Fran Lacombe

Employee

Grant K. Walkup, PhD

Employee

Jay Vaithilingam

Employee

Jenny Che

Employee

Kate McSheffrey

Employee

Laura J. Palermino

Employee

Osman Emara

Employee

Patrizio Renzetti

Employee

Thomas Roddy

Employee

Tien Dao

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 5, 2021
BioSpace
Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPSTM (Multiple Antigen Presenting System) platform , today announced that Elizabeth Radcliffe has joined the company as Chief Financial Officer.
DelveInsight Business Research, LLP
May 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's Biliary Tract Cancers (BTC) Market Insights report lays forward comprehensive insights into current treatment practices,...
Nick Paul
January 27, 2021
FierceBiotech
A second phase 3 trial of Agios Pharmaceuticals' mitapivat has hit its primary endpoint in patients with pyruvate kinase deficiency, keeping the biotech on track to file for approval on both sides of the Atlantic in the coming months.
Amirah Al Idrus
December 20, 2020
FierceBiotech
Agios Pharmaceuticals' roots are in cancer drug development, but it's passing that baton to Servier as it doubles down on its programs in genetically defined diseases, including a drug it's developing for noncancerous blood diseases. The deal will see $1.8 billion changing hands upfront, but it could reach $2 billion in value if vorasidenib, a clinical-stage asset, hits certain goals.
Nick Paul
December 1, 2020
FierceBiotech
A phase 3 trial of Agios Pharmaceuticals' mitapivat in a form of anemia has met its primary endpoint. The success gives Agios some of the data it needs to file for approval of the drug in pyruvate kinase deficiency next year.
June 9, 2020
BioSpace
Thermo Fisher Scientific to Co-develop a Global Companion Diagnostic for Low-grade Glioma with Agios Pharmaceuticals - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.